Phenytoin toxicity secondary to an oxcarbazepine-phenytoin 2C19 interaction.
BACKGROUND
Polytherapy is common in the management of bipolar disorder, as are the side effects associated with this treatment strategy.


OBJECTIVE
The authors review the literature on drug-drug interactions involving oxcarbazepine and identify specific mechanisms that may have clinical importance.


METHODS
The authors provide a case report of a patient who developed phenytoin toxicity associated with an oxcarbazepine-phenytoin interaction.


RESULTS
Co-administration of phenytoin and oxcarbazepine resulted in toxic levels of phenytoin. Therefore, the patient's daily dosage of oxcarbazepine and phenytoin were reduced.


CONCLUSIONS
Although oxcarbazepine is an inducer of the 3A4 isoenzyme, it acts as an inhibitor of the 2C19 isoenzyme, and it can raise levels of other agents, for example, phenytoin, that are also metabolized by this isoenzyme.
correspondence and M.D., Massachusetts General Hospital-McLean Dept. of Psychiatry, Boston, MA, USA. dsoskin@partners.org
David P
DP
Soskin
Ari J
AJ
Kane
Theodore A
TA
Stern
D000368:Aged; D000927:Anticonvulsants / Q000009:adverse effects*; D001714:Bipolar Disorder / Q000188:drug therapy*; D002220:Carbamazepine / Q000009:adverse effects / Q000031:analogs & derivatives*; D004347:Drug Interactions; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000078330:Oxcarbazepine; D010672:Phenytoin / Q000009:adverse effects*
D000927:Anticonvulsants; D002220:Carbamazepine; D010672:Phenytoin; D000078330:Oxcarbazepine